公开(公告)号：US20240350639A1

公开(公告)日：2024-10-24

申请号：US18606927

申请日：2024-03-15

申请人： Astellas Institute for Regenerative Medicine

发明人： Roger Gay ,  Judson Ratliff ,  Romma E. Southwick

IPC分类号： A61K47/26 ,  A61K9/08 ,  A61K31/7004 ,  A61K31/728 ,  A61K33/06 ,  A61K33/14 ,  A61K35/28 ,  A61K35/30 ,  A61K47/02 ,  A61K47/12 ,  A61K47/36 ,  A61P27/02

CPC分类号： A61K47/26 ,  A61K9/08 ,  A61K31/7004 ,  A61K31/728 ,  A61K33/06 ,  A61K33/14 ,  A61K35/28 ,  A61K35/30 ,  A61K47/02 ,  A61K47/12 ,  A61K47/36 ,  A61P27/02

摘要： Some aspects of this disclosure provide clinical media that support viability, re-plating efficiency, and repopulation capacity of cells and tissues during storage for up to 48 hours or longer. The clinical media provided herein are also useful for clinical irrigation. Cell or tissue preparations comprising a cell population or tissue and a clinical medium as provided herein are also provided, as are methods for generating such preparations. Methods for using the clinical media and cell and tissue preparations provided herein, for example, for administering an effective amount of cells or tissue to a subject in need thereof, are also disclosed.

公开(公告)号：US12016879B2

公开(公告)日：2024-06-25

申请号：US16171678

申请日：2018-10-26

申请人： Boston Scientific Scimed, Inc. ,  Mayo Foundation for Medical Education and Research

发明人： Sarah M. Gruba ,  Douglas D. Pagoria ,  James P. Rohl ,  Stephen J. Hahn ,  Suraj Kapa ,  Chance M. Witt

IPC分类号： A61B18/14 ,  A61K9/00 ,  A61K33/06 ,  A61K33/14 ,  A61K33/42 ,  A61B18/00

CPC分类号： A61K33/06 ,  A61B18/1492 ,  A61K9/0009 ,  A61K33/14 ,  A61K33/42 ,  A61B2018/0022 ,  A61B2018/00238 ,  A61B2018/00351 ,  A61B2018/00577 ,  A61B2018/00613 ,  A61B2018/00839

摘要： In various aspects, the present disclosure provides methods for applying ablation therapy to a target tissue region within a patient, which methods include: (a) navigating a catheter to a target tissue region within the patient, the catheter including an elongate body having a proximal portion and a distal portion and a balloon structure positioned at the distal portion of the elongate body, which balloon structure may be permeable to a calcium-ion-containing solution that comprises one or more calcium salts; (b) positioning the balloon structure at the target tissue region; (c) delivering energy to the target tissue region; and (d) eluting the calcium-ion-containing solution from the balloon structure before, during, and/or after delivering the energy to the target tissue region. In various other aspects, the present disclosure provides apparatuses that can be used for performing such methods, among others.

公开(公告)号：US11998564B2

公开(公告)日：2024-06-04

申请号：US17413567

申请日：2018-12-14

申请人： National Taiwan University

发明人： Yih-Sharng Chen ,  Li-Jiuan Shen ,  Mei-Hsin Lin ,  Heng-Wen Chou

IPC分类号： A61K33/06 ,  A61K9/08 ,  A61K31/047 ,  A61K31/133 ,  A61K33/04 ,  A61K33/14

CPC分类号： A61K33/06 ,  A61K9/08 ,  A61K31/047 ,  A61K31/133 ,  A61K33/04 ,  A61K33/14

摘要： The present invention is a cardioplegic solution that demonstrates better stability in pH, particulate matter formation and osmolality but at the same time demonstrates superior ability to preserve heart functions than currently available cardioplegic solutions. The cardioplegic solution comprises potassium (K+), magnesium (Mg2+), sodium (Na+), chloride (Cl−), gluconate, acetate, sulfate (SO42−), THAM and mannitol dissolved in water.

公开(公告)号：US20240148608A1

公开(公告)日：2024-05-09

申请号：US18393974

申请日：2023-12-22

申请人： MEDISCA PHARMACEUTIQUE INC.

发明人： Panagiota DANOPOULOS

IPC分类号： A61J1/05 ,  A61J3/04 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K31/045 ,  A61K31/135 ,  A61K31/137 ,  A61K31/192 ,  A61K31/195 ,  A61K31/196 ,  A61K31/197 ,  A61K31/351 ,  A61K31/4418 ,  A61K31/4422 ,  A61K31/445 ,  A61K31/4458 ,  A61K31/565 ,  A61K31/57 ,  A61K31/7048 ,  A61K33/14 ,  A61K47/10 ,  A61K47/26 ,  A61K47/38 ,  A61K47/42 ,  A61K47/46 ,  B01F29/00 ,  B01F29/10 ,  B01F29/32 ,  B01F31/00 ,  B01F35/22 ,  B01F35/42 ,  B65B7/16

CPC分类号： A61J1/05 ,  A61J3/04 ,  A61K9/0034 ,  A61K9/06 ,  A61K9/107 ,  A61K31/045 ,  A61K31/135 ,  A61K31/137 ,  A61K31/192 ,  A61K31/195 ,  A61K31/196 ,  A61K31/197 ,  A61K31/351 ,  A61K31/4418 ,  A61K31/4422 ,  A61K31/445 ,  A61K31/4458 ,  A61K31/565 ,  A61K31/57 ,  A61K31/7048 ,  A61K33/14 ,  A61K47/10 ,  A61K47/26 ,  A61K47/38 ,  A61K47/42 ,  A61K47/46 ,  B01F29/10 ,  B01F29/32 ,  B01F29/40 ,  B01F29/401 ,  B01F29/4011 ,  B01F29/40221 ,  B01F31/00 ,  B01F35/2209 ,  B01F35/421 ,  B65B7/16 ,  B01F29/40365

摘要： A dispensing container and adapter system for use with a planetary mixer is disclosed. The dispensing container has a longitudinal axis and a transverse axis. The dispensing container may include a nozzle and a removable cap to cover the nozzle. The removable cap may have a first width dimension measured along the transverse axis. The dispensing container may include a body having a second width dimension measured along the transverse axis. An adapter may receive the dispensing container. The adapter may include a cavity to receive the removable cap. The cavity may have a cavity width that exceeds the first width dimension. The adapter may also include a recess for receiving a portion of the dispensing container. The recess may extend from the cavity. At least a portion of the recess may have a width dimension smaller than both the first width dimension and the second width dimension.

公开(公告)号：US20240101422A1

公开(公告)日：2024-03-28

申请号：US18225852

申请日：2023-07-25

申请人： Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

发明人： Craig Sherman ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC分类号： C01B17/64 ,  A61K9/00 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/573 ,  A61K31/60 ,  A61K31/727 ,  A61K33/00 ,  A61K33/04 ,  A61K33/14 ,  A61K33/22 ,  A61K45/06

CPC分类号： C01B17/64 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/573 ,  A61K31/60 ,  A61K31/727 ,  A61K33/00 ,  A61K33/04 ,  A61K33/14 ,  A61K33/22 ,  A61K45/06 ,  C01P2006/80 ,  Y10T436/23

摘要： Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

公开(公告)号：US11938255B2

公开(公告)日：2024-03-26

申请号：US16971879

申请日：2019-02-27

申请人： TERUMO KABUSHIKI KAISHA

发明人： Hiroaki Takahashi

IPC分类号： A61M1/28 ,  A61K9/08 ,  A61K31/70 ,  A61K31/7004 ,  A61K33/14 ,  A61K47/02 ,  A61K47/26 ,  A61K9/00 ,  A61P7/08

CPC分类号： A61M1/287 ,  A61K9/08 ,  A61K31/7004 ,  A61K33/14 ,  A61K47/02 ,  A61K47/26 ,  A61K9/0019 ,  A61P7/08

摘要： The present invention is to provide a means capable of properly balancing water and sodium in peritoneal dialysis treatment, without causing hyponatremia, while avoiding adversely affecting residual renal function. A peritoneal dialysate containing 1.5 to 1.8 w/v % of glucose and 120 to 130 mEq/L of sodium, and being for independent use once or twice a day, wherein the peritoneal dialysate is used in combination with another peritoneal dialysate that contains 1.35 to 2.5 w/v % of glucose and 132 to 135 mEq/L of sodium, in peritoneal dialysis that involves injection of an amount of 1.5 to 2.0 L per one time in an abdominal cavity of a subject, storage and drainage three to five times a day.

公开(公告)号：US11931378B2

公开(公告)日：2024-03-19

申请号：US17551882

申请日：2021-12-15

申请人： Alfaisal University

发明人： Souraya Goumri-Said ,  Mohammed Benali Kanoun ,  Salamat Ali ,  Junaid Haider ,  Ali Haider ,  Muhammad Ikram

IPC分类号： A61K33/14 ,  A61K9/08 ,  A61K47/02 ,  A61K47/36 ,  A61P31/04 ,  C01F11/24 ,  C08L5/08

CPC分类号： A61K33/14 ,  A61K9/08 ,  A61K47/02 ,  A61K47/36 ,  A61P31/04 ,  C01F11/24 ,  C08L5/08

摘要： Strontium oxide (SrO) nanoparticle and various concentrations of chitosan (CS)-doped SrO nanocomposite were synthesized via co-precipitation method. A variety of characterization techniques including were done for characterizing and qualifying the nanocomposite. X-ray powder diffraction affirmed cubic and tetragonal structure of SrO nanoparticle and CS-doped SrO nanocomposite with a decrease in crystallinity upon doping. Fourier transform infrared spectrum endorsed existing functional groups on CS/SrO surfaces while d-spacing was estimated using high resolution Transmission electron microscopes images. UV-Visible and Photoluminescence spectroscopy spectra showed an increase in band gap energies with an increase in doping concentration. Elemental composition of CS-doped SrO nanocomposite deposited with different doping concentrations was studied using Energy dispersive Spectroscopy. Addition of chitosan resulted in the formation of nanocomposite and rod-like structures that led to enhanced catalytic activity during methylene blue ciprofloxacin degradation in the presence of reducing agent sodium borohydrate at various pH conditions.

公开(公告)号：US20240058267A1

公开(公告)日：2024-02-22

申请号：US18140124

申请日：2023-04-27

申请人： MIRAKI INNOVATION THINK TANK LLC

发明人： Christopher VELIS ,  Karen MILLER ,  Tarik S. CHAUDHRY ,  Emilia JAVORSKY ,  William Roger MAILWARNING-BURTON ,  Bradley Leo GUERTIN ,  Avi Aaron KURLANTZICK

IPC分类号： A61K9/10 ,  A61K9/00 ,  A61K33/14 ,  A61K47/38 ,  A61M5/32

CPC分类号： A61K9/10 ,  A61K9/0019 ,  A61K33/14 ,  A61K47/38 ,  A61M5/32

摘要： Slurries comprise liquid water, about 2% to about 70% ice by volume, and one or more additives affecting flowability and/or tonicity of the slurry. Solutions for making a slurry comprise liquid water and one or more additives affecting flowability of the slurry. Flowability of the slurry relates to ice particles capable of flowing through a cannula, such as a needle. The slurry is suitable for injection into subcutaneous fat of a human subject for removal of adipose tissue.

公开(公告)号：US11903986B2

公开(公告)日：2024-02-20

申请号：US15680998

申请日：2017-08-18

申请人： Akrivista LLC

发明人： Scott Whitcup ,  Orest Olejnik ,  Michael Garst

IPC分类号： A61K9/00 ,  A61K36/185 ,  A61K36/61 ,  A61K31/7048 ,  A61K9/08 ,  A61K9/107 ,  A61K36/534 ,  A61K36/752 ,  A61K36/235 ,  A61K31/045 ,  A61K33/14 ,  A61K47/26 ,  A61K47/10 ,  A61K47/32 ,  A61K47/38 ,  A61K33/00 ,  A61K33/20 ,  A61K33/22 ,  A61K47/18 ,  G01N33/487 ,  G01N33/84 ,  G01N33/68 ,  A61K36/54 ,  A61K45/06

CPC分类号： A61K36/185 ,  A61K9/0048 ,  A61K9/08 ,  A61K9/107 ,  A61K9/1075 ,  A61K31/045 ,  A61K31/7048 ,  A61K33/00 ,  A61K33/14 ,  A61K33/20 ,  A61K33/22 ,  A61K36/235 ,  A61K36/534 ,  A61K36/54 ,  A61K36/61 ,  A61K36/752 ,  A61K45/06 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  G01N33/487 ,  G01N33/6827 ,  G01N33/6893 ,  G01N33/84 ,  G01N2800/16

摘要： In preferred the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.

公开(公告)号：US20240050470A1

公开(公告)日：2024-02-15

申请号：US18489703

申请日：2023-10-18

申请人： Corvitus LLC ,  Corvitus GmbH

发明人： Tracy Goeken ,  Bernard Winkler

IPC分类号： A61K33/42 ,  A61K33/06 ,  A61K38/06 ,  A61K33/14 ,  A61K31/7004 ,  A61K31/375 ,  A61K31/198 ,  A61K31/205 ,  A61P9/10 ,  A61K9/00

CPC分类号： A61K33/42 ,  A61K33/06 ,  A61K38/063 ,  A61K33/14 ,  A61K31/7004 ,  A61K31/375 ,  A61K31/198 ,  A61K31/205 ,  A61P9/10 ,  A61K9/0019

摘要： A method to inhibit reperfusion injury to a tissue that has experienced ischemia comprising treating the ischemic tissue with an antioxidant solution prior to or in conjunction with reperfusion of blood into the ischemic tissue pursuant to artery bypass surgery, angioplasty or in conjunction with an angiogram. The antioxidant solution is comprised of water, dissolved salts of calcium, potassium, magnesium, sodium, one or more buffers, L-Arginine, glucose, glutathione, and ascorbic acid and wherein the solution is ionically and pH balanced to a physiologic pH, preferably 7.2-7.4.